Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
novel_miRNA_2 mimic
- Development stage
- Preclinical
- Lead developer
- Henry Ford Health
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
novel_miRNA_2 mimic is a synthetic microRNA mimic of a previously unannotated human microRNA, novel_miRNA_2 (sequence: UCCCUGUUCGGGCGCCACU), which acts as an endogenous suppressor of pathological subchondral bone remodeling during early-stage osteoarthritis (OA). Developed by researchers at Henry Ford Health, Michigan State University, and the University Health Network, the mimic functions as a canonical microRNA that is loaded into Argonaute 2 (AGO2)-containing RNA-induced silencing complexes (RISCs) to downregulate target genes involved in osteogenesis and mineralization, including RUNX2, ALPL, and IL11. In preclinical models, systemic delivery of the novel_miRNA_2 mimic during early-stage knee OA significantly reduces cartilage damage and osteophyte burden, demonstrating potential as a disease-modifying therapeutic.
- Other names
- novel_miRNA_2
02
Targets
ALPL (Tissue-nonspecific alkaline phosphatase)IL11 (Interleukin-11)RUNX2
Beyond the preview
Go deeper on novel_miRNA_2 mimic.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on novel_miRNA_2 mimic.